Effects of Shugan Jianpi Huayu decoction combined with Entecavir in treatment of pulmonary tuberculosis complicated with chronic hepatitis B
Objective:To observe effects of Shugan Jianpi Huayu decoction combined with Entecavir in treatment of pulmonary tuberculosis complicated with chronic hepatitis B (CHB). Methods:A prospective study was conducted on 81 patients with pulmonary tuberculosis complicated with CHB admitted to the hospital from September 2021 to September 2023. According to the random number table method,they were divided into 41 cases in the control group and 40 cases in the study group. The control group was treated with Entecavir orally,while the study group was treated with Shugan Jianpi Huayu decoction on the basis of that of the control group. The therapeutic effect,the levels of liver function indexes[aspartate aminotransferase (AST),total bilirubin (TBIL),serum alanine aminotransferase (ALT)],the liver fibrosis indexes[type Ⅲ procollagen (PC Ⅲ),type Ⅳ collagen (Ⅳ-C),hyaluronic acid (HA),laminin (LN)]and the coagulation function indexes[thrombin time (TT),activated partial thromboplastin time (APTT),prothrombin time (PT),fibrinogen (FIB)]before and after the treatment,and the incidence of adverse reactions were compared between the two groups. Results:The lesion absorption rate,the sputum smear negative conversion rate and the hepatitis B virus negative conversion rate in the study group were higher than those in the control group,and the differences were statistically significant (P<0.05). The levels of ALT,TBIL and AST in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant (P<0.05). The levels of PC Ⅲ,Ⅳ-C,HA and LN in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant (P<0.05). The levels of TT,APTT and PT in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;the FIB levels of the two groups were higher than those before the treatment,and that in the study group was higher than that in the control group;and the differences were statistically significant (P<0.05). However,there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusions:Shugan Jianpi Huayu decoction combined with Entecavir in the treatment of the patients with pulmonary tuberculosis complicated with CHB can improve the lesion absorption rate,the sputum smear negative rate and the HBV negative conversion rate,improve the levels of coagulation function indexes,and reduce the levels of liver function indexes and liver fibrosis indexes.Moreover,it is superior to simple Entecavir oral treatment.
Shugan Jianpi Huayu decoctionEntecavirPulmonary tuberculosisChronic hepatitis BLiver functionLiver fibrosisCoagulation function
万方数据
维普
